Movement Alert｜CARsgen Therapeutics-B Declines 5.19% in Regular Trading, Dilutive Impact of Discounted Placement Continues to Pressure Stock

Market Focus05-28

On May 28, CARsgen Therapeutics-B declined 5.19% in regular trading, trading at HK$17.18/share, with trading volume of HK$27.94 million.

The decline was primarily driven by the ongoing dilutive effect of the company's recently completed share placement. CARsgen completed a top-up placement of 23.7 million shares at HK$19.84 per share, representing approximately 4.15% of pre-placement issued share capital. The placement, arranged by UBS and Macquarie, raised net proceeds of approximately HK$4.62 billion. Following completion, total issued shares increased to approximately 594.68 million. The placement price represents a discount to prior trading levels, and shareholder dilution concerns continue to weigh on sentiment.

Additionally, the broader Hong Kong biotech sector exhibited weakness, with INNOVENT BIO down 2.03%, AKESO down 2.08%, BEIGENE down 2.21%, and 3SBIO down 4.82%, amplifying individual stock pressure.

CARsgen Therapeutics is an investment holding company focused on developing CAR-T cell therapies for hematological malignancies, solid tumors, and autoimmune diseases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145278169?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 10:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145278169","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CARsgen Therapeutics-B Declines 5.19% in Regular Trading, Dilutive Impact of Discounted Placement Continues to Pressure Stock","media":"Market Focus","content":"<p><p>On May 28, CARsgen Therapeutics-B declined 5.19% in regular trading, trading at HK$17.18/share, with trading volume of HK$27.94 million.</p><p>The decline was primarily driven by the ongoing dilutive effect of the company's recently completed share placement. CARsgen completed a top-up placement of 23.7 million shares at HK$19.84 per share, representing approximately 4.15% of pre-placement issued share capital. The placement, arranged by UBS and Macquarie, raised net proceeds of approximately HK$4.62 billion. Following completion, total issued shares increased to approximately 594.68 million. The placement price represents a discount to prior trading levels, and shareholder dilution concerns continue to weigh on sentiment.</p><p>Additionally, the broader Hong Kong biotech sector exhibited weakness, with INNOVENT BIO down 2.03%, AKESO down 2.08%, BEIGENE down 2.21%, and 3SBIO down 4.82%, amplifying individual stock pressure.</p><p>CARsgen Therapeutics is an investment holding company focused on developing CAR-T cell therapies for hematological malignancies, solid tumors, and autoimmune diseases.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CARsgen Therapeutics-B Declines 5.19% in Regular Trading, Dilutive Impact of Discounted Placement Continues to Pressure Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CARsgen Therapeutics-B Declines 5.19% in Regular Trading, Dilutive Impact of Discounted Placement Continues to Pressure Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-28 10:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 28, CARsgen Therapeutics-B declined 5.19% in regular trading, trading at HK$17.18/share, with trading volume of HK$27.94 million.</p><p>The decline was primarily driven by the ongoing dilutive effect of the company's recently completed share placement. CARsgen completed a top-up placement of 23.7 million shares at HK$19.84 per share, representing approximately 4.15% of pre-placement issued share capital. The placement, arranged by UBS and Macquarie, raised net proceeds of approximately HK$4.62 billion. Following completion, total issued shares increased to approximately 594.68 million. The placement price represents a discount to prior trading levels, and shareholder dilution concerns continue to weigh on sentiment.</p><p>Additionally, the broader Hong Kong biotech sector exhibited weakness, with INNOVENT BIO down 2.03%, AKESO down 2.08%, BEIGENE down 2.21%, and 3SBIO down 4.82%, amplifying individual stock pressure.</p><p>CARsgen Therapeutics is an investment holding company focused on developing CAR-T cell therapies for hematological malignancies, solid tumors, and autoimmune diseases.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1145278169","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145278169","pubTimestamp":1779936386,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 28, CARsgen Therapeutics-B declined 5.19% in regular trading, trading at HK$17.18/share, with trading volume of HK$27.94 million.The decline was primarily driven by the ongoing dilutive effect...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"动向提示|科济生物-B常规交易下跌5.19%，折价配售摊薄影响继续令股价承压","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"On May 28, CARsgen Therapeutics-B declined 5.19% in regular trading, trading at HK$17.18/share, with trading volume of HK$27.94 million.The decline was primarily driven by the ongoing dilutive effect of the company's recently completed share placement. CARsgen completed a top-up placement of 23.7 million shares at HK$19.84 per share, representing approximately 4.15% of pre-placement issued share capital. The placement, arranged by UBS and Macquarie, raised net proceeds of approximately HK$4.62 billion. Following completion, total issued shares increased to approximately 594.68 million. The placement price represents a discount to prior trading levels, and shareholder dilution concerns continue to weigh on sentiment.Additionally, the broader Hong Kong biotech sector exhibited weakness, with INNOVENT BIO down 2.03%, AKESO down 2.08%, BEIGENE down 2.21%, and 3SBIO down 4.82%, amplifying individual stock pressure.CARsgen Therapeutics is an investment holding company focused on developing CAR-T cell therapies for hematological malignancies, solid tumors, and autoimmune diseases.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145278169","isCrawlerRequest":true}